NCT06580639 The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
| NCT ID | NCT06580639 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Linkoeping University |
| Condition | Tuberculosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 280 participants |
| Start Date | 2020-08-01 |
| Primary Completion | 2025-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 280 participants in total. It began in 2020-08-01 with a primary completion date of 2025-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about how the blood leucocytes from patients with and without exposure or disease from tuberculosis (TB) are able to kill live mycobacteria (M. tuberculosis). The main question it aims to answer is: Is intracellular growth suppression of M. tuberculosis in peripheral blood mononuclear cells variable among healthy blood donors and higher than in patients with latent TB compared to active TB?
Eligibility Criteria
Inclusion Criteria: Healthy blood donors or subjects who will get vaccinated. Exclusion Criteria:Known HIV infection, not Swedish citizen, chronic liver och kidney disease,immunosuppression from treatment or disease.
Contact & Investigator
Thomas Schoen, Professor
PRINCIPAL INVESTIGATOR
Linkoeping University
Frequently Asked Questions
Who can join the NCT06580639 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06580639 currently recruiting?
Yes, NCT06580639 is actively recruiting participants. Contact the research team at tschon@hotmail.com for enrollment information.
Where is the NCT06580639 trial being conducted?
This trial is being conducted at Kalmar, Sweden, Linköping, Sweden.
Who is sponsoring the NCT06580639 clinical trial?
NCT06580639 is sponsored by Linkoeping University. The principal investigator is Thomas Schoen, Professor at Linkoeping University. The trial plans to enroll 280 participants.